Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5163676 | 1.00 | TSHR (0.46) | TSHRCYP1A2CYP2C19CYP2C9KCNN4 | |
| SCHEMBL4295864 | 1.00 | TSHR (0.46) | TSHRCYP1A2CYP2C19CYP2C9KCNN4 | |
| SCHEMBL6860953 | 0.79 | MEN1 (0.54) | TSHRSMN1; SMN2HIF1ALMNAHTT | |
| SCHEMBL9317685 | 0.78 | TSHR (0.48) | TSHRCYP1A2CYP2C19CYP2C9KCNN4 | |
| SCHEMBL7476372 | 0.78 | TSHR (0.48) | TSHRCYP1A2CYP2C19CYP2C9KCNN4 | |
| SCHEMBL11444310 | 0.77 | TSHR (0.42) | TSHRCYP1A2CYP2C19CYP2C9KCNN4 | |
| SCHEMBL4634423 | 0.77 | SCN5A (0.47) | TSHRL3MBTL1 | |
| Hydrochloric Acid SCHEMBL11308929 | 0.76 | TSHR (0.46) | TSHRCYP1A2CYP2C19CYP2C9KCNN4 | |
| SCHEMBL3046939 | 0.76 | TAAR1 (0.48) | TSHRCYP1A2CYP2C19CYP2C9KCNN4 | |
| SCHEMBL23781410 | 0.75 | TSHR (0.50) | TSHRCYP1A2CYP2C19KCNN4HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117568296-A | P450 hydroxylase mutant and synthetic R-halohydrin thereof | 遵义医科大学 | 2024-02-20 | — | — | CN | disclosed |
| EP-1790337-A2 | Methods and compounds for treating depression and other disorders | NPS PHARMACEUTICALS, INC. (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1096926-B1 | METHODS AND COMPOUNDS FOR TREATING DEPRESSION | NPS PHARMA INC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20040039014-A1 | Methods and compounds for treating depression and other disorders | NPS PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | disclosed |
| EP-1096926-A2 | METHODS AND COMPOUNDS FOR TREATING DEPRESSION | NPS PHARMACEUTICALS, INC. (US) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000002551-A2 | METHODS AND COMPOUNDS FOR TREATING DEPRESSION | NPS PHARMACEUTICALS, INC. (US) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039014-A1 | Methods and compounds for treating depression and other disorders | GRIN1, GRIN2C, GRIN3B | TSHR 1030/4885CYP1A2 2625/4885CYP2C19 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.